Earnings ·
Amarin Corporation plc reported financial results for the second quarter and first half of 2026
AMRNAmarin Corp Plcuk
Amarin Corporation plc reported financial results for the second quarter and first half of 2026. Total net revenue declined to $42.2 million from $72.7 million in Q2 2025, primarily due to a $25 million upfront payment received in the prior year period associated with its exclusive license agreement with Recordati S.p.A. for European commercialization. Operating expenses decreased by 59% to $27.0 million as the company completed its $70 million annual cost savings initiative. The company reported a net loss of $7.7 million, compared to $14.1 million in Q2 2025, and maintained a cash position of $314.6 million while remaining debt-free. In-market demand for VASCEPA/VAZKEPA grew 59% year-over-year across its global partner network, with European demand rising 69%. Amarin operates in the pharmaceutical industry, developing and commercializing cardiovascular treatments.